Rani N. Al Karmi, MD, FRCS(c), M.Ed, a research and clinical fellow in Cornea and External Disease at Mass. Eye and Ear, was selected as the 2017 Alcon Research Scholar. This award provides support to a trainee to allow them to work on a translational research project with a senior clinician scientist at Mass. Eye and Ear. Dr. Al Karmi will work with Reza Dana, MD, MSc, MPH
The Tear Film & Ocular Surface Society (TFOS) and the Alliance for Eye and Vision Research (AEVR) will co-host a Congressional briefing about dry eye disease on July 12. Janine Clayton, MD (National Institutes of Health), Susan Vitale, PhD, MHS (National Eye Institute), Anat Galor, MD (Bascom Palmer), Victor Perez, MD (Duke University as of August 2017), Carolyn Begley, OD, MS (Indiana University) and Laura Periman, MD (Redmond Eye Clinic, Seattle), will be joining
Ophthalmologists at Mass. Eye and Ear among most experienced nationwide to offer newly FDA-approved laser vision correction technology.
Boston, Mass. — Ophthalmologists at Massachusetts Eye and Ear are now offering a new type of minimally-invasive laser vision correction, the ReLEx® SMILE procedure. FDA-approved in 2016, and with more than 750,000 procedures performed worldwide each year, SMILE is a proven laser procedure for the treatment of myopia (nearsightedness). Mass. Eye and Ear specialists are
Treating donor tissue with a special cocktail of molecules improves outcomes and promotes survival of high-risk corneal transplants
Boston, Mass. — Treating donor corneas with a cocktail of molecules prior to transplanting to a host may improve survival of grafts and, thus, outcomes in high-risk corneal transplant patients, according to a new study led by researchers at Massachusetts Eye and Ear. The findings,
Findings may lead to the development of therapies to prevent damage to the retina, the light-sensitive tissue at the back of the eye.
Boston, Mass. — Chemical eye burns caused by alkali agents not only injure the front of the eye — the cornea, where the contact takes place — but also cause widespread damage to the light-sensitive tissue at the back of the eye (the retina) as well, often leading to optic nerve damage and glaucoma. In a report
Deborah Pavan-Langston, MD, FACS—Harvard Ophthalmology alumna and Professor Emeritus—received the Claes Dohlman Society Award at the Cornea Society/Eye Bank Association of America 2016 Fall Educational Symposium. This lifetime achievement award recognizes her excellence in teaching and contributions to the field of cornea and external disease.
Dr. Langston is the first person to receive all three of the highest honors in cornea: the Castroviejo Medal for Outstanding Contributions to the Field of Corneal and Anterior Segment Disease (American Academy of Ophthalmology), the
Findings published in the American Journal of Pathology offer new directions for treatment of patients with Fuchs’ Endothelial Corneal Dystrophy (FECD)
Boston, Mass. — Researchers from Massachusetts Eye and Ear have, for the first time, identified rapidly proliferating cells (known as “neural crest-derived progenitor cells”) in the corneal endothelium of specimens from normal corneas and from corneas with Fuchs’ Endothelial Corneal Dystrophy (FECD), a condition in which the cells responsible for keeping the cornea
Researchers at Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that contribute to optic nerve damage following keratoprosthesis (KPro) implantation in a mouse model. They have also shown that blocking one of the factors, TNFa, leads to a significant decrease in optic nerve cell death, suggesting a new direction for preventing optic nerve damage in patients with keratoprosthesis implants.